CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.